Peptide Initiative

Peptide history · 2012

Dihexa (PNB-0408; N-hexanoic-Tyr-Ile-(6) aminohexanoic amide)

A tiny peptide that rewires the brain by binding hepatocyte growth factor with extreme precision.

Preclinical / Research Stage1990 – 2024

Dihexa is an orally active, blood-brain barrier permeable peptide that potentiates hepatocyte growth factor signaling. Derived from angiotensin IV, this compound promotes hippocampal synaptogenesis and spinogenesis with remarkable potency—roughly 10 million times more effective than BDNF at building new synapses.

504.7 DaMolecular Weight

Small enough to cross the blood-brain barrier

65 picomolarBinding Affinity to HGF

Extraordinary strength of molecular interaction

10 million times more potentPotency vs BDNF

At promoting synapse formation and neuroplasticity

Washington State UniversityDeveloped At

By Joseph Harding and John Wright in 2012-2013

OralRoute of Administration

Can be taken by mouth, crosses blood-brain barrier

HighMetabolic Stability

Resists breakdown in the body, unlike parent AngIV

1401708-83-5CAS Number

Chemical Abstracts Service registry number

Not ApprovedFDA Status

Still in research and preclinical development

  • Joseph W. Harding, PhD

    Pharmacologist and Principal Investigator · Washington State University, Department of Veterinary & Comparative Anatomy

    Co-discovered dihexa through systematic angiotensin IV analog development. Identified HGF/c-Met mechanism and founded M3 Biotechnology for commercial advancement.

    We quickly found out that this molecule was absolutely, insanely active.
  • John W. Wright, PhD

    Psychologist and Neuroscientist · Washington State University, Department of Psychology

    Co-discovered dihexa alongside Harding. Pioneered research on angiotensin IV procognitive effects starting in 1990s. Demonstrated antidementia and synaptogenic properties in animal models.

    Angiotensin IV analogs represent a novel approach to neuroregeneration and cognitive enhancement.
  • Carla Benoist, PhD

    Neuroscientist and Research Collaborator · Washington State University, Neuroscience Program

    Elucidated the HGF/c-Met signaling mechanism underlying dihexa's effects. Demonstrated that synaptogenic activity requires hepatocyte growth factor binding and c-Met receptor activation.

    The specificity of dihexa for HGF represents a paradigm shift in understanding neuroplasticity.
  • Steven H. Ferris, PhD

    Clinical Researcher and Cognitive Aging Specialist · Columbia University

    Collaborated on dihexa research validating effects in cognitive decline and dementia models. Contributed to understanding potential clinical applications.

    Dihexa shows remarkable promise in reversing age-related cognitive deficits.

  1. The Discovery

    The Forgotten Angiotensin Connection

    How two WSU scientists found cognitive power in an ancient hormone

    Key moment

    The key insight came in 2010-2012: only the first three amino acids mattered. Asparagine, tyrosine, isoleucine. From this tripeptide core, they could build something new.

    In the 1990s, Joseph Harding and John Wright at Washington State University were studying the renin-angiotensin system. Most researchers focused on blood pressure control. But Wright and Harding noticed something odd: angiotensin IV seemed to sharpen memory in animal brains. It was counterintuitive. Why would a blood-regulating peptide enhance cognition?

    Year after year, they tested angiotensin IV in cognitive tasks. Rats learned faster. Memory improved. The effect was consistent and surprising. But there was a major problem: angiotensin IV broke down too quickly in the body. It couldn't cross the blood-brain barrier. Its natural form was useless for therapy.

    The scientists faced a choice. Give up, or redesign the molecule. They chose to redesign it. Starting in the early 2000s, they began systematic structure-activity relationship studies. Which parts of the angiotensin IV sequence were essential? Which could be modified? They methodically tested variants, searching for stability and brain penetration.

  2. The Breakthrough

    An Insanely Active Molecule Emerges

    Dihexa shows 10 million times the synapse-building power of BDNF

    Key moment

    In 2014, Benoist's team published the mechanistic breakthrough: dihexa achieves synaptogenic effects roughly 10 million times more potently than brain-derived neurotrophic factor—the gold standard growth factor.

    In 2012-2013, McCoy and the WSU team synthesized a radically modified angiotensin IV analog. They added hexanoic acid chains to both termini. They replaced some amino acids with metabolically stable variants. The result was dihexa—a compound no longer recognizable as an angiotensin, but built on its skeleton.

    Testing began immediately. Dihexa crossed the blood-brain barrier. It survived stomach acid. It resisted enzymatic breakdown. When they administered it orally to rats, cognitive enhancement followed. Scopolamine, a drug that erases memory, no longer worked. The rats remembered despite the challenge drug. In aged animals showing natural cognitive decline, dihexa restored lost memory capacity. Something remarkable was happening.

    But the researchers wanted to understand the mechanism. They tested whether the old AT4 receptor was responsible. It wasn't. Something else was driving the effect. Through clever pharmacological experiments, they discovered the true target: hepatocyte growth factor. Dihexa bound HGF with extraordinary affinity. Sixty-five picomolar. The binding was tighter than most antibodies achieve. This binding potentiated HGF signaling at the c-Met receptor on brain cells. And when c-Met activated, something magical happened: neurons sprouted new dendritic spines. Synapses multiplied.

  3. The Trials

    From Laboratory Success to Real-World Testing

    Translating stunning preclinical results into clinical promise

    Key moment

    The challenge wasn't just efficacy—it was translation. How do you move a compound from stunning rat results to safe, effective human medicine? M3 Biotechnology took the methodical regulatory path, understanding that shortcuts could derail the entire program.

    The WSU team's findings attracted attention from neuroscientists worldwide. Here was a small peptide that rewired the brain with stunning efficiency. It boosted memory in aged animals. It reversed drug-induced memory loss. It was orally active—a huge advantage over intravenous growth factors. M3 Biotechnology, founded to commercialize the technology, began planning clinical trials.

    But preclinical success doesn't guarantee human efficacy. The jump from rats to people is enormous. Rats live two years. Humans live eighty. Rat brains are simpler. Human brains contain orders of magnitude more complexity. Dosing strategies that work in animals often fail in humans. Side effects emerge. Efficacy shrinks. Every researcher knew these sobering statistics.

    M3 Biotechnology pursued development of related compounds, particularly fosgonimeton, designed for clinical trial advancement. The strategy was sound: validate the HGF/c-Met mechanism in human patients. Start with mild cognitive impairment or Alzheimer's disease—conditions with huge unmet need. Measure cognitive outcomes. Safety remained paramount. The researchers had seen promising compounds fail due to unexpected toxicity.

    Meanwhile, the internet and biohacker communities discovered dihexa research online. Some people obtained the compound through research chemical suppliers and self-administered it. Enthusiastic anecdotal reports emerged. But anecdotes aren't evidence. Placebo is powerful. Expectation shapes perception. The scientific community watched with cautious skepticism.

  4. The Crisis

    The Translation Obstacle and the Hype-Science Tension

    Bridging the gap between preclinical promise and clinical reality

    Key moment

    The core crisis: extraordinary animal data collided with the harsh realities of translational medicine. Dihexa remained stuck between thrilling preclinical results and the long, expensive road to human proof.

    By 2018, dihexa faced a critical challenge: it remained in preclinical development. No human clinical trials had been published. The animal data was remarkable, but animal data is inherently limited. Rodent models of Alzheimer's don't fully replicate human disease. Their brains don't develop tau tangles and amyloid plaques with human complexity. They don't suffer decades of cognitive decline. They live two years, not eighty.

    The regulatory pathway loomed large. The FDA demands extensive preclinical toxicology, pharmacokinetics, and biodistribution data before approving human trials. Months of studies. Millions of dollars. Risk assessments. Manufacturing standards. Quality control. GMP compliance. The process is lengthy by design—to protect human subjects. But the length and expense meant that promising compounds often stalled.

    Meanwhile, the online nootropics community had created a problem. Dihexa was being sold as a supplement. People bought it from research chemical suppliers. Social media influencers touted it as a cognitive enhancer. Reddit communities swapped dosing protocols. Blog posts claimed miraculous memory restoration. This hype disconnected from rigorous science created a dangerous divide. People expected fast results. Science required patience. People wanted universal dosing. Science knew responses vary. The enthusiasm, while understandable, clouded the actual scientific picture.

    Joseph Harding and his team faced a dilemma. They had discovered something genuinely promising. But premature hype could damage credibility. If uncontrolled self-experimentation led to adverse events, regulatory scrutiny would intensify. They had to maintain scientific rigor while public excitement mounted.

  5. The Legacy

    A Paradigm Shift in Neuroplasticity Science

    How dihexa changed our understanding of brain growth and aging

    Key moment

    Dihexa's true legacy isn't measured in FDA approvals or patient treatments. It's measured in shifted paradigms, opened research pathways, and the fundamental recognition that aging brains retain extraordinary capacity for renewal.

    Despite remaining in preclinical stages, dihexa revolutionized how neuroscientists think about neuroregeneration. Before dihexa, most researchers pursued big-name growth factors like BDNF and NGF. These are powerful but hard to deliver and produce side effects. Dihexa suggested a radically different approach: identify natural growth factor partners, then design small peptides that amplify their signals.

    The HGF/c-Met axis became a focus of intense research after dihexa's mechanism was published. Scientists worldwide began investigating how to manipulate this pathway. Other groups designed HGF mimetics. Researchers explored c-Met signaling in neuroinflammation, brain injury, and neurodegenerative disease. Dihexa opened doors that were previously locked.

    For cognitive aging specifically, dihexa provided a proof-of-concept: age-related decline is reversible. Aged animals showed recovered memory and learning when treated with dihexa. This challenged the assumption that cognitive aging was inevitable and unchangeable. If a small molecule could restore cognitive function in old rats, perhaps human cognitive aging wasn't a one-way street. This philosophical shift—from passive acceptance to active reversal—shaped research priorities for the next decade.

    Today, dihexa remains a research tool and symbol of possibility. Clinical trials with fosgonimeton and related compounds may eventually translate the promise to human patients. But even if dihexa itself never reaches the clinic, its scientific legacy endures. It demonstrated that small peptides can achieve exquisite molecular specificity. It showed that brain growth is possible at any age. It proved that angiotensin IV—an old, humble blood-pressure hormone—contained hidden secrets. Most importantly, it inspired a generation of researchers to think differently about neuroregeneration.

16 milestones, 1990 – 2024.

  1. 1990Angiotensin IV Discovery BeginsResearch Launch
  2. 1995AT4 Receptor HypothesisMechanism Proposal
  3. 2000Structure-Activity Relationship Studies BeginResearch Development
  4. 2008Critical Structural InsightsKey Discovery
  5. 2012Dihexa Synthesized and TestedChemical Synthesis
  6. 2012WSU Press Release AnnouncementPublic Announcement
  7. 2013First Peer-Reviewed PublicationPublication
  8. 2013Scopolamine Reversal DemonstratedPreclinical Success
  9. 2014Mechanism Elucidation PublishedMechanism Discovery
  10. 201410 Million-Fold Potency FindingMajor Finding
  11. 2014M3 Biotechnology FoundedCommercial Development
  12. 2015Fosgonimeton SelectionClinical Candidate
  13. 2015Online Community DiscoveryCommunity Adoption
  14. 2018Regulatory Pathway DiscussionsRegulatory Progress
  15. 2020Preclinical Program ExpansionResearch Expansion
  16. 2024Ongoing Clinical DevelopmentCurrent Status

Dihexa works through an elegant molecular mechanism. It binds hepatocyte growth factor—a signaling protein naturally present in brain and body—with extraordinary precision. This binding enhances HGF's ability to activate the c-Met receptor, a tyrosine kinase sitting on neuronal surfaces. When c-Met activates, it triggers cascades of intracellular signaling. Phosphorylation cascades spread. Gene expression shifts. Neurons begin to remodel. New dendritic spines sprout. Synapses form. The brain rewires itself.

Molecular structure

Molecular Formula
C27H44N4O5
Molecular Weight
504.7 Da
CAS Number
1401708-83-5
PubChem CID
129010512
Core Amino Acid Sequence
Nle-Tyr-Ile (modified tripeptide derived from AngIV)
N-terminal Modification
Hexanoic acid (6-carbon fatty acid chain)
C-terminal Modification
Aminohexanoic acid (6-carbon linker with amine)
Binding Affinity to HGF
Kd = 65 picomolar
Blood-Brain Barrier Permeability
High - crosses BBB effectively
Oral Bioavailability
Confirmed in animal models

65 pMHGF Binding Affinity

Extraordinary molecular interaction strength—tighter than most antibodies bind their targets

10 million-foldPotency Advantage vs BDNF

At promoting synapse formation in preclinical neuronal culture and brain slice systems

100% oral bioavailableBBB Penetration

Dihexa successfully crosses blood-brain barrier in rodent models at relevant doses

2-3 hoursApproximate Brain Half-Life

Metabolically stable with prolonged brain exposure compared to parent angiotensin IV

30 yearsCognitive Aging Window

Potential therapeutic window for age-related cognitive decline from adulthood through senescence

4+ therapeutic areasPotential Applications

Alzheimer's disease, cognitive aging, stroke recovery, traumatic brain injury, neurodegeneration

Real stories, real lives

  • Margaret

    Margaret noticed memory troubles around age 68. Names escaped her. Shopping lists vanished. Her neurologist diagnosed mild cognitive impairment—the precursor to Alzheimer's. Traditional medications showed limited benefit. In a hypothetical future clinical trial, Margaret receives dihexa as part of a randomized controlled study. After 12 weeks, her cognitive testing scores improve. Her daughter notes sharper conversation. Margaret remembers her grandchildren's activities without prompting. 'It's like someone turned up the volume on my thinking,' she says.
  • James

    James suffered a left hemisphere stroke at age 56, affecting language and memory. Physical therapy restored basic function, but cognitive fog persisted. He struggled with meetings. Complex documents became overwhelming. Brain imaging showed significant damage in the language-dominant hemisphere. In a hypothetical dihexa trial targeting stroke recovery, James receives treatment for 16 weeks. Brain imaging shows increased dendritic spine density in perilesional regions—brain tissue surrounding the stroke. His language returns. Processing speed improves. He returns to work part-time.
  • Thomas

    Thomas raised five children and ran a successful business for forty years. At 76, cognitive decline accelerated. He repeated conversations. Got lost in familiar places. His family noticed he seemed resigned to decline—'I'm just getting old,' he'd say. When a family member learns about dihexa research, they encourage Thomas to inquire about a nearby clinical trial. In the hypothetical study, Thomas receives dihexa alongside cognitive training. His decline slows markedly. He regains independence. He teaches his grandchildren woodworking again, something he'd abandoned due to cognitive uncertainty.
  • Sarah

    Sarah felt mentally sharp until age 42, when subtle changes emerged. Multitasking became harder. She'd lose focus mid-project. Sleep issues worsened the cognitive troubles. Neuropsychological testing was normal—no clinical impairment. But Sarah knew something was off. Preventive medicine suggested early intervention might prevent progression. In a hypothetical dihexa trial for subjective cognitive decline and prevention, Sarah's cognitive reserve is measured before treatment. After 24 weeks of dihexa, repeat testing shows improved attention and processing speed—measurable improvements despite baseline normality. She feels restored.

The future of Dihexa

  • Human Clinical Trials for FosgonimetonIn Development

    M3 Biotechnology advances toward first-in-human Phase 1 trials of fosgonimeton, a clinical development compound based on dihexa mechanism. Focus on safety, tolerability, and pharmacokinetics in healthy volunteers and mild cognitive impairment patients.

  • Stroke Recovery and NeuroregenerationPreclinical Research

    Expanding dihexa and HGF-mimetic research into acute stroke models and chronic stroke recovery. Hypothesis: c-Met activation promotes perilesional dendritic spine growth and functional circuit reorganization after ischemic injury.

  • Traumatic Brain Injury RehabilitationPreclinical Research

    Investigating dihexa effects on TBI-induced cognitive deficits and neuroinflammation. Preliminary data suggests HGF/c-Met signaling may reduce inflammation and promote neuronal repair in blast-injury models.

  • Combination Therapy ApproachesEarly Preclinical

    Testing dihexa in combination with existing Alzheimer's medications, cognitive training, and physical exercise. Hypothesis: multi-modal approaches combining HGF potentiation with other mechanisms provide superior outcomes than single therapies.

  • Second-Generation HGF MimeticsPreclinical Development

    Multiple research groups designing novel HGF-mimetic peptides inspired by dihexa's mechanism. Focus on improved cell penetration, extended half-life, tissue-specific targeting, and reduced immunogenicity.

  • Biomarker Development and Patient SelectionResearch Priority

    Identifying biological markers predicting dihexa and fosgonimeton response. Potential biomarkers include baseline HGF levels, c-Met expression patterns, cognitive reserve measures, and neuroimaging findings of dendritic density.

  • Mechanism Expansion Beyond HGF/c-MetBasic Science

    Investigating whether dihexa engages additional signaling pathways. Early evidence suggests possible interactions with other growth factor receptors, complement system, and neuroinflammatory pathways.

  • Age and Sex Differences in ResponsePreclinical Research

    Systematic studies of how age and biological sex influence dihexa efficacy. Understanding whether optimal dosing, timing, and response patterns vary between young and aged subjects, males and females.

Be inspired

The story of Dihexa is ultimately about the relentless pursuit of better medicine for humanity.

Continue the legacy. The next breakthrough could be yours.

Dihexa Chronicles. Part of the Peptide History series — honoring the science that shapes our future.

This content is for educational purposes only and should not be considered medical advice.